Log in
Log in
Or log in with
GoogleGoogle
Twitter Twitter
Facebook Facebook
Apple Apple     
Sign up
Or log in with
GoogleGoogle
Twitter Twitter
Facebook Facebook
Apple Apple     

TAKEDA PHARMACEUTICAL COMPANY LIMITED

(4502)
  Report
Delayed Japan Exchange  -  02:00 2022-09-30 am EDT
3767.00 JPY   -0.24%
11:38aTakeda - Strengthening Healthcare Systems to Meet Patients Need for Plasma-Derived Therapies
AQ
09/29Strengthening Healthcare Systems to Meet Patients' Need for Plasma-Derived Therapies
BU
09/29Takeda Pharmaceutical Company Limited and United Nations Institute for Training and Research Strengthening Healthcare Systems to Meet Patients' Need for Plasma-Derived Therapies
CI
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisionsFunds 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector newsMarketScreener Strategies

Takeda Pharmaceutical's First-Quarter Net Profit Fell 24% From High Base

07/28/2022 | 02:52am EDT

By Kosaku Narioka


Takeda Pharmaceutical Co. said Thursday that first-quarter net profit slid 24% due to a high base a year earlier, despite broad-based gains in drug sales.

The Japanese drugmaker said net profit for the quarter ended June 30 rose to 105.01 billion yen ($768.7 million) from Y137.68 billion a year earlier, which had been boosted by its divestment of diabetes products in Japan. The quarterly net profit was largely in line with the estimate of Y105.67 billion from a poll of analysts by Quick.

First-quarter revenue increased 2.4% to Y972.465 billion thanks partly to a weaker yen. U.S. revenue rose 22% to Y501.1 billion.

Drug sales increased across various business areas. Sales of ulcerative colitis drug Entyvio rose 34% from a year earlier to Y168.3 billion.

Takeda kept its revenue and net profit forecasts for the fiscal year ending March 2023. It continued to expect revenue to increase 3.4% to Y3.690 trillion and net profit to rise 27% to Y292.00 billion.


Write to Kosaku Narioka at kosaku.narioka@wsj.com


(END) Dow Jones Newswires

07-28-22 0251ET

All news about TAKEDA PHARMACEUTICAL COMPANY LIMITED
11:38aTakeda - Strengthening Healthcare Systems to Meet Patients Need for Plasma-Derived Ther..
AQ
09/29Strengthening Healthcare Systems to Meet Patients' Need for Plasma-Derived Therapies
BU
09/29Takeda Pharmaceutical Company Limited and United Nations Institute for Training and Res..
CI
09/29TAKEDA PHARMACEUTICAL COMPANY LIMITED : Ex-dividend..
FA
09/27Takeda Pharmaceutical Company Limited Issues Notice of Redemption to the Holders of 4.4..
CI
09/20Puma Biotech in Exclusive License Deal With Takeda
DJ
09/20Takeda Pharmaceutical Says Health Canada Authorized Treatment for Post-Transplant Cytom..
MT
09/20Health Canada approves Takeda's LIVTENCITY™ (maribavir) the First and Only Treatm..
AQ
09/19Takeda Signs Virtual Power Purchase Agreement with Enel North America to Advance Renewa..
BU
09/16Takeda Pharmaceutical Says It Received Positive Opinion for Post-Transplant Cytomegalov..
MT
More news
Analyst Recommendations on TAKEDA PHARMACEUTICAL COMPANY LIMITED
More recommendations
Financials
Sales 2023 3 781 B 26 131 M 26 131 M
Net income 2023 311 B 2 153 M 2 153 M
Net Debt 2023 2 916 B 20 154 M 20 154 M
P/E ratio 2023 18,8x
Yield 2023 4,78%
Capitalization 5 845 B 40 398 M 40 398 M
EV / Sales 2023 2,32x
EV / Sales 2024 2,24x
Nbr of Employees 47 347
Free-Float 96,4%
Chart TAKEDA PHARMACEUTICAL COMPANY LIMITED
Duration : Period :
Takeda Pharmaceutical Company Limited Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends TAKEDA PHARMACEUTICAL COMPANY LIMITED
Short TermMid-TermLong Term
TrendsBearishNeutralBullish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 15
Last Close Price 3 767,00 JPY
Average target price 4 588,00 JPY
Spread / Average Target 21,8%
EPS Revisions
Managers and Directors
Christophe Weber Chief Operating & Corporate Officer
Constantine Saroukos Chief Financial Officer & Director
Masami Iijima Chairman
Andrew S. Plump Director, President-Research & Development
Michael E. Mendelsohn Chief Medical & Scientific Officer
Sector and Competitors
1st jan.Capi. (M$)
TAKEDA PHARMACEUTICAL COMPANY LIMITED20.37%40 544
JOHNSON & JOHNSON-4.51%432 579
ELI LILLY AND COMPANY19.47%313 567
ROCHE HOLDING AG-15.52%269 089
ABBVIE INC.5.41%252 343
PFIZER, INC.-25.89%247 841